Log In
Print
BCIQ
Print
Print this Print this
 

CV9201

  Manage Alerts
Collapse Summary General Information
Company CureVac GmbH
DescriptionVaccine comprised of modified mRNA components coding for 5 different antigens frequently expressed on NSCLC cells
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today